Brought to you by 
GSK signs second agreement with Santaris Pharma, this one involving LNA technology
27 Feb 2014
Executive Summary
A day after announcing a Locked Nucleic Acid (LNA) drug discovery deal with Roche, Santaris Pharma AS (oligonucleotides) teamed up with GlaxoSmithKline PLC, which received an option to use LNA to research, develop, and market drug candidates targeting up to three RNA molecules.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK signs second agreement with Santaris Pharma, this one involving LNA technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice